Patent protection for a newly introduced drug on the market lasts almost 20 years. During this time, no other company (except the one with the patent) has the right to produce it. When protection ends, the drug may be manufactured by other manufacturers who begin to compete with each other – such competing drugs are called generics.
The original and generic medicine may differ in name, manufacturer and price. However, the active substance contained in them, which is responsible for the action of the drug, and its amount will always be the same. Thanks to the guarantee of equally high production standards and constant monitoring of safety and effectiveness, patients can freely choose the product that best suits them in the pharmacy. The manufacturing process of generic drugs must follow the principles of Good Manufacturing Practice (GMP). Compliance with the GMP rules allows for the provision of good quality medical devices.
The Polish Public Procurement Office has issued recommendations regarding indications and requirements related to public procurement for IT systems.
The guidelines are divided into two volumes and together they provide a collection of information on public procurement of IT systems. The first volume presents recommendations and guidelines relating to preparatory activities prior to the commencement of a public procurement procedure for information systems, while Volume II is devoted to recommendations and guidelines relating to the description of the subject of a contract and preparation of a public procurement procedure for information systems.
KIELTYKA GLADKOWSKI KG LEGAL takes part in the project “Systemic Design and Sustainable Healthcare for MedTech Manufacturing (SysteMA)”. One of elements of the project is led by the Life Science Cluster in Krakow and the MedSilesia cluster. The latter became involved in activities to raise awareness and knowledge in the field of the circular economy.
The research is part of the EIT Manufacturing project SysteMA (Systemic Design and Sustainable Healthcare for MedTech Manufacturing), which focuses on the role of MedTech manufacturing towards the environmental, social, and economic sustainability of healthcare systems. The project aims to create online training courses on this topic, providing EU companies with actionable skills to improve the sustainability of their products and processes and seize new market opportunities.
KIELTYKA GLADKOWSKI KG LEGAL took part in a hybrid meeting organized by the New York City Bar Association, devoted to “Non-Fungible Tokens (NFTs) and the Regulatory Landscape in Latin America and the U.S.”
New York City Bar is a voluntary association of professional lawyers and students, founded in 1870. Nowadays, New York City Bar associates 25000 members. KIELTYKA GLADKOWSKI joined the organization and its lawyers are associated as international lawyers.
